Simtra BioPharma Solutions Releases First Sustainability Report, Underscoring Commitment to Responsible Growth
PARSIPPANY, N.J., May 1, 2025 /PRNewswire/ — Simtra BioPharma Solutions, a leading contract development and manufacturing organization (CDMO) specializing in sterile injectables, today announced the publication of its inaugural Sustainability Report for the year ended December 31, 2024.
'Since becoming an independent company in 2023, environmental, social and governance-related matters have played a vital role in shaping the way we do business, supporting our employees, our customers, and engaging with our local communities,' said Franco Negron, CEO of Simtra BioPharma Solutions. 'As such, we are proud to publish our first full-length Sustainability Report.'
Key highlights of the 2024 report include:
Conducted its first greenhouse gas (GHG) emissions inventory and set waste reduction goals aligned with ISO 14001 and ISO 50001 certifications, utilizing modern equipment to ensure sustainable and efficient operations.
Recycled 51% of its waste across manufacturing sites and offset approximately 1,400 tons of CO2 from solar panels installed at the Germany site.
Grew employee base by 26% and revamped onboarding and training programs.
Completed more than 430 supplier diligence checks; became EcoVadis rated.
Established a dedicated Sustainability Committee to oversee progress and drive initiatives across the organization.
'This report is a starting point,' said James Garrett, General Counsel and Chief Compliance Officer of Simtra BioPharma Solutions. 'It shows where we are today, where we need to go, and how we will hold ourselves accountable as we build the premier CDMO for injectable products.'
To learn more about Simtra BioPharma Solutions' commitment to sustainability, view the full report here: Simtra Sustainability Report 2024
About Simtra BioPharma Solutions
As the premier, independently owned Contract Development Manufacturing Organization with more than 65 years of sterile injectable manufacturing expertise, Simtra BioPharma Solutions offers world-class cGMP sterile fill and finish, technical expertise, quality service, and a uniquely collaborative approach to support our customers' strategic objectives.
For more information, visit www.simtra.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
38 minutes ago
- Malaysian Reserve
The Endpoint Detection & Response Solutions Users Report Stand Up To Today's Threats: New Rankings Published By Info-Tech Research Group for 2025
The 2025 Endpoint Detection and Response Data Quadrant Report from research and advisory firm Info-Tech Research Group names the leading EDR solutions for enhancing threat detection and incident response. The report's findings are based on authentic user feedback and data collected through the firm's SoftwareReviews platform. TORONTO, June 27, 2025 /PRNewswire/ – Info-Tech Research Group has released its annual Endpoint Detection & Response (EDR) Data Quadrant Report, recognizing five top-ranked champions for 2025. Based on data from SoftwareReviews, a division of the global research and advisory firm, the report provides organizations with key insights to help identify top EDR software solutions. These tools combine endpoint management and antivirus capabilities to detect, respond to, and eliminate malicious threats, helping IT teams stay ahead of increasingly sophisticated cyberattacks. EDR solutions are critical for identifying, analyzing, and neutralizing cyber threats across devices and networks. As cyberattacks grow more complex and persistent, organizations are looking beyond basic antivirus tools and considering adoption of platforms that offer real-time visibility, automation, and rapid incident response. Info-Tech's Data Quadrant is a comprehensive evaluation tool that uses the feedback of IT professionals to rank software products based on likeliness to recommend, features scores, net emotional footprint score, and vendor capabilities. These dimensions are aggregated into a Composite Score (CS), which reflects overall user satisfaction and determines the product's placement within the Data Quadrant. The firm's methodology ensures that rankings are based entirely on authentic user reviews, free from analyst opinions or vendor influence. Data from 512 end-user reviews on Info-Tech's SoftwareReviews platform was used to identify the top EDR software providers for the 2025 Endpoint Detection & Response Data Quadrant report. The 2025 Endpoint Detection & Response – Champions are as follows: ThreatDown EDR, 9.1 CS, ranked high for its effective whitelisting and blacklisting capabilities. Crowdstrike Falcon Platform, 8.9 CS, ranked high for its robust intrusion detection and prevention features. Defender for Endpoint, 8.6 CS, ranked high for its quality of features. Singularity Platform, 8.4 CS, ranked high for its strong continuous monitoring functionality. Huntress Security Platform, 8.3 CS, ranked high for its dependable automated threat response tools. The insights are published to support organizations evaluating solutions to strengthen threat detection, streamline incident response, and enhance overall cybersecurity posture. User assessments of software categories on SoftwareReviews provide an accurate and detailed view of the constantly changing market. Info-Tech's reports are informed by the data from users and IT professionals who have intimate experience with the software throughout the procurement, implementation, and maintenance processes. Read the full report: Best 2025 Endpoint Detection & Response Software Solutions For more information about Info-Tech's SoftwareReviews, the Data Quadrant, or the Emotional Footprint, or to access resources to support the software selection process, visit About Info-Tech Research Group Info-Tech Research Group serving over 30,000 IT and HR professionals. The company produces unbiased, highly relevant research and provides advisory services to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide them with everything they need, from actionable tools to analyst guidance, ensuring they deliver measurable results for their organizations. To learn more about Info-Tech's divisions, visit McLean & Company for HR research and advisory services and SoftwareReviews for software buying insights. Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact pr@ For information about Info-Tech Research Group or to access the latest research, visit and connect via LinkedIn and X. About SoftwareReviews SoftwareReviews is a division of Info-Tech Research Group, SoftwareReviews empowers organizations with the best data, insights, and advice to improve the software buying and selling experience. For buyers, SoftwareReviews' proven software selection methodologies, customer insights, and technology advisors help maximize success with technology decisions. For providers, the firm helps build more effective marketing, product, and sales processes with expert analysts, how-to research, customer-centric marketing content, and comprehensive analysis of the buyer landscape.
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Xlence as Diamond Sponsor of The Trading Show 2025 in Casablanca
Award-winning CFD broker to showcase cutting-edge multi-asset technology and thought leadership on 12–13 July at the Hyatt Regency Casablanca DUBAI, UAE, June 28, 2025 /PRNewswire/ — Xlence, a rapidly expanding worldwide CFD broker, has been named a Diamond Sponsor of The Trading Show 2025, which will be held on July 12 and 13, 2025, at the Hyatt Regency Casablanca in Morocco. This sponsorship marks the end of a record-breaking quarter for the company. At the Smart Vision Summit in Oman in March 2025, Xlence was named the Fastest-Growing FX Broker. This showed that Xlence was making progress in extending market access and innovation across North Africa and beyond. The Trading Show is Africa's biggest event, bringing together institutional investors, brokers, fintech pioneers, and exchanges to define the region's financial future. The broker aims to strengthen its ties with North African traders by attending the event in Casablanca. Nicolas Georgiou, PR & Communications Lead at Xlence, remarked, 'Casablanca is quickly becoming a hub for CFD trading in North Africa.' 'Our Diamond Sponsorship shows that we are committed to this area for the long term and gives traders a chance to try out our conditions and talk to our team directly.' Morocco's rapid adoption of electronic trading and the Casablanca Stock Exchange's record-breaking success in 2024 make it an ideal location for Xlence to expand. The broker's cloud-native architecture and dedication to trader education make it a suitable choice for both institutional and retail clients seeking performance, transparency, and scalability. About Xlence Xlence is a global CFD broker committed to delivering a transparent, innovative, and comprehensive trading experience. Headquartered in Dubai and expanding globally, Xlence combines cutting-edge platforms with professional support to help traders excel in dynamic markets. Website: Media ContactNicolas Georgiou – PR & Communicationsinfo@ 96199856 Risk Warning: All trading involves risk. Please ensure you fully understand the risks involved. Logo – View original content:
Malaysian Reserve
11 hours ago
- Malaysian Reserve
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, June 27, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the 'Class Period'). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025. So What: If you purchased Sarepta Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Sarepta class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (3) the severity of adverse events from ELEVIDYS treatment would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (4) as a result of the foregoing, Defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Sarepta class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Kim, Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827case@
